AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie other Key Products Portfolio — Worldwide net revenues ($M) ($M)
Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues
Latest, FY2025
3,736
Period ended Dec 31, 2025
Change on a year earlier
+2.4%
3,648 in FY2024
History
8 years
Since FY2018
Sources
8
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Other Key Products Portfolio — Worldwide net revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3,736 | +2.4% | Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗ |
| FY2024 | Dec 31, 2024 | 3,648 | -4.2% | Form 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗ |
| FY2023 | Dec 31, 2023 | 3,806 | -1.2% | Form 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗ |
| FY2022 | Dec 31, 2022 | 3,854 | -29.8% | Form 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗ |
| FY2021 | Dec 31, 2021 | 5,489 | +6.9% | Form 8-K (abbv-20211231xexhibit991.htm, filed 2022-02-02) ↗ |
| FY2020 | Dec 31, 2020 | 5,134 | +7.2% | Form 8-K (abbv-20201231xexhibit991.htm, filed 2021-02-03) ↗ |
| FY2019 | Dec 31, 2019 | 4,789 | -3.2% | Form 8-K (abbv-20191231xexhibit9.htm, filed 2020-02-07) ↗ |
| FY2018 | Dec 31, 2018 | 4,948 | – | Form 8-K (abbv-20181231xexhibit991.htm, filed 2019-01-25) ↗ |
Breakdown
What makes up other key products portfolio — worldwide net revenues ($m)
- Other Key Products Portfolio — U.S. net revenues ($M)3,011 · FY2025
- Other Key Products Portfolio — International net revenues ($M)725 · FY2025
- Other Key Products Portfolio — Worldwide reported growth YoY (%)2.4% · FY2025
- Other Key Products Portfolio — Worldwide operational (constant-currency) growth YoY (%)2.2% · FY2025
- Mavyret (glecaprevir/pibrentasvir — Hepatitis C) — Worldwide net revenues ($M)1,317 · FY2025
- Creon (pancrelipase) — Worldwide net revenues ($M)1,512 · FY2025
- Linzess/Constella (linaclotide) — Worldwide net revenues ($M)907 · FY2025
- All Other Products — Worldwide net revenues ($M)2,627 · FY2025
Cite this data
StockData. (2026). AbbVie Other Key Products Portfolio — Worldwide net revenues ($M) ($M), annual FY2018–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/ta_other_key_ww
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.